Arcturus Therapeutics Holdings (ARCT) Other Accumulated Expenses (2018 - 2019)
Arcturus Therapeutics Holdings (ARCT) reported Other Accumulated Expenses of $560000.0 for Q3 2019, down 55.34% quarter-over-quarter from $1.3 million in Q2 2019.
Arcturus Therapeutics Holdings (ARCT) Other Accumulated Expenses (2018 - 2019) Analysis & Trends
Arcturus Therapeutics Holdings has reported Other Accumulated Expenses for 2 years, with the latest figure at $560000.0 in Q3 2019.
- For the quarter ending Q3 2019, Other Accumulated Expenses changed N/A year-over-year to $560000.0; the trailing twelve-month figure through Sep 2019 stood at $560000.0 (changed N/A YoY), and the FY2018 full-year result was $674000.0, changed N/A from the prior year.
- Other Accumulated Expenses for Q3 2019 stood at $560000.0, down from $1.3 million in the prior quarter.
- The five-year high for Other Accumulated Expenses was $1.3 million in Q2 2019, with the low at $560000.0 in Q3 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Arcturus Therapeutics Holdings | 217.14 Mn | 5.76 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2019 | 560,000.00 |
| Jun 30, 2019 | 1.25 Mn |
| Dec 31, 2018 | 674,000.00 |